CA2459348C - Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions - Google Patents

Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions Download PDF

Info

Publication number
CA2459348C
CA2459348C CA2459348A CA2459348A CA2459348C CA 2459348 C CA2459348 C CA 2459348C CA 2459348 A CA2459348 A CA 2459348A CA 2459348 A CA2459348 A CA 2459348A CA 2459348 C CA2459348 C CA 2459348C
Authority
CA
Canada
Prior art keywords
functional
receptors
antibody
cells
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2459348A
Other languages
English (en)
French (fr)
Other versions
CA2459348A1 (en
Inventor
Angus Gidley-Baird
Julian Alexander Barden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosceptre International Ltd
Original Assignee
Biosceptre International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Priority claimed from PCT/AU2002/000061 external-priority patent/WO2002057306A1/en
Application filed by Biosceptre International Ltd filed Critical Biosceptre International Ltd
Publication of CA2459348A1 publication Critical patent/CA2459348A1/en
Application granted granted Critical
Publication of CA2459348C publication Critical patent/CA2459348C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2459348A 2001-09-03 2002-09-03 Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions Expired - Lifetime CA2459348C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome
AUPR7431 2001-09-03
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic
AUPR7430 2001-09-03
PCT/AU2002/000061 WO2002057306A1 (en) 2001-01-17 2002-01-17 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
AUPCT/AU02/00061 2002-01-17
PCT/AU2002/001204 WO2003020762A1 (en) 2001-09-03 2002-09-03 Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions

Publications (2)

Publication Number Publication Date
CA2459348A1 CA2459348A1 (en) 2003-03-13
CA2459348C true CA2459348C (en) 2013-06-18

Family

ID=41706691

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2459348A Expired - Lifetime CA2459348C (en) 2001-09-03 2002-09-03 Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions

Country Status (9)

Country Link
JP (1) JP4467973B2 (zh)
CN (2) CN100497386C (zh)
AU (1) AU2002322192B2 (zh)
CA (1) CA2459348C (zh)
MY (1) MY142283A (zh)
NZ (2) NZ549019A (zh)
TW (1) TWI329648B (zh)
WO (1) WO2003020762A1 (zh)
ZA (1) ZA200402630B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1961767T3 (da) 2001-01-17 2012-05-29 Biosceptre Int Ltd Diagnose og behandling af cancere og andre lidelser
EP1570232B1 (en) * 2002-12-05 2016-11-02 KLA-Tencor Technologies Corporation Apparatus and methods for detecting overlay errors using scatterometry
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
NZ583896A (en) 2007-09-14 2011-05-27 Biosceptre Int Ltd Purinergic (p2x) receptors in extra-cellular body fluid
CN102143978B (zh) * 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
CN101469352B (zh) * 2008-08-29 2011-12-21 苏州福英基因科技有限公司 一种早期子宫癌原位杂交检测试剂盒
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
AU2011301153B2 (en) * 2010-09-10 2014-11-27 Biosceptre International Limited Companion animal treatments
BR112013033974A2 (pt) 2011-07-01 2017-02-14 Biosceptre Int Ltd terapia de combinação
EP2990800A1 (en) * 2014-08-29 2016-03-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Neprilysin as heartfailure (HF) prognostic marker
WO2017041143A1 (en) 2015-09-11 2017-03-16 Ctm@Crc Ltd. Chimeric antigen receptors and uses thereof
JP7127021B2 (ja) * 2016-10-21 2022-08-29 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 細胞傷害性粒子
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
DK1961767T3 (da) * 2001-01-17 2012-05-29 Biosceptre Int Ltd Diagnose og behandling af cancere og andre lidelser

Also Published As

Publication number Publication date
NZ549019A (en) 2008-05-30
CN100497386C (zh) 2009-06-10
TWI329648B (en) 2010-09-01
WO2003020762A1 (en) 2003-03-13
AU2002322192B2 (en) 2008-05-01
JP4467973B2 (ja) 2010-05-26
JP2005513416A (ja) 2005-05-12
MY142283A (en) 2010-11-15
CN101445555B (zh) 2013-07-03
CN101445555A (zh) 2009-06-03
NZ565994A (en) 2010-02-26
CN1625565A (zh) 2005-06-08
ZA200402630B (en) 2005-06-29
CA2459348A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
US10450380B2 (en) Polypeptide immunogen for generating an antibody to non-functional P2X7 receptor
CA2459348C (en) Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
AU2002322192A1 (en) Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions
JP2003508525A (ja) 抗腫瘍抗体、タンパク質、及びそれらの使用
Barden et al. Non-functional P2X 7 receptor

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220906